FDA orders tissue-recovery firm to stop manufacturing
This article was originally published in RAJ Devices
The US Food and Drug Administration (FDA) has ordered a US human tissue-recovery firm based in Raleigh, North Carolina and its owner, to stop all manufacturing operations after inspections found serious deficiencies in its manufacturing practices. Donor Referral Services and its owner, Philip Guyett, were also ordered to retain the human cells, tissues and cellular and tissue-based products (HCT/Ps) recovered on or after 25 May 2005 and which were still in the company's possession.
You may also be interested in...
Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.
The proposal, which would increase capacity for pandemic supplies, is similar to ideas President Trump embraced pre-pandemic.
Sanofi has named the head of its new API business; Sweden's Enzymatica has hired talent from J&J and L'Oreal; and Bayer has a new transformation officer.